Phenotypes Associated with This Genotype

Genotype
MGI:5517428

• Allelic Composition: Gt(ROSA)26Sor^tm1Jus/Gt(ROSA)26Sor⁺; Tg(Mx1-cre)1Cgn/0
• Genetic Background: involves: C57BL/6 * C57BL/6J * C57BL/6N * CBA

• ♀: phenotype observed in females
• ♂: phenotype observed in males
• N: normal phenotype

mortality/aging

premature death ( J:202090 )

• median survival is 41 days post pIpC treatment

immune system

enlarged thymus ( J:202090 )

• in diseased pIpC-treated mice

abnormal thymus physiology ( J:202090 )

• lymphoid infiltration in the thymus at 6 months in pIpC-treated mice

enlarged spleen ( J:202090 )

• in diseased pIpC-treated mice

abnormal leukocyte morphology ( J:202090 )

• monomorphic, enlarged white blood cells with a high nuclear:chromatin ratio (consistent with leukemic blasts) at 6 months in pIpC-treated mice

decreased pro-B cell number ( J:202090 )

• in pIpC-treated mice

arrested B cell differentiation ( J:202090 )

• nearly all B cells are arrested in the early pro-B stage of pIpC-treated mice

decreased double-positive T cell number ( J:202090 )

• in the thymus of pIpC-treated mice

decreased B cell number ( J:202090 )

• in the spleen of pIpC-treated mice

decreased mature B cell number ( J:202090 )

• in pIpC-treated mice

decreased pre-B cell number ( J:202090 )

• in pIpC-treated mice

increased leukocyte cell number ( J:202090 )

• at 6 months in pIpC-treated mice

increased CD8-positive, alpha-beta T cell number ( J:202090 )

• in the thymus of pIpC-treated mice

increased single-positive T cell number ( J:202090 )

• immature single positive cells in the thymus of pIpC-treated mice

increased large unstained cell number ( J:202090 )

• large, unstained cells (abnormal blasts) in the peripheral blood at 6 months in pIpC-treated mice

intermingled spleen red and white pulp ( J:202090 )

• disrupted separation between white and red pulp by infiltrating lymphoblasts at 6 months in pIpC-treated mice

enlarged lymph nodes ( J:202090 )

• in diseased pIpC-treated mice

increased inflammatory response ( J:202090 )

• lymphoid infiltration in the spleen, interstitial and perivascular space of the kidney, perivascular cuffs in the liver, meninges surrounding the brain, thymus, stomach and intestine at 6 months in pIpC-treated mice

intestinal inflammation ( J:202090 )

• lymphoid infiltration in the intestine at 6 months in pIpC-treated mice

stomach inflammation ( J:202090 )

• lymphoid infiltration in the stomach at 6 months in pIpC-treated mice

meningitis ( J:202090 )

• lymphoid infiltration in the meninges surrounding the brain at 6 months in pIpC-treated mice

liver inflammation ( J:202090 )

• lymphoid infiltration in the perivascular cuffs in the liver at 6 months in pIpC-treated mice

kidney inflammation ( J:202090 )

• lymphoid infiltration in the interstitial and perivascular space of the kidney at 6 months in pIpC-treated mice

digestive/alimentary system

intestinal inflammation ( J:202090 )

• lymphoid infiltration in the intestine at 6 months in pIpC-treated mice

stomach inflammation ( J:202090 )

• lymphoid infiltration in the stomach at 6 months in pIpC-treated mice

neoplasm

increased acute lymphoblastic leukemia incidence ( J:202090 )

• pIpC-treated mice rapidly develop and succumb to acute leukemia

behavior/neurological

lethargy ( J:202090 )

growth/size/body

distended abdomen ( J:202090 )

• in diseased pIpC-treated mice

enlarged kidney ( J:202090 )

• in diseased pIpC-treated mice

enlarged liver ( J:202090 )

• in diseased pIpC-treated mice

enlarged spleen ( J:202090 )

• in diseased pIpC-treated mice

respiratory system

respiratory distress ( J:202090 )

liver/biliary system

enlarged liver ( J:202090 )

• in diseased pIpC-treated mice

liver inflammation ( J:202090 )

• lymphoid infiltration in the perivascular cuffs in the liver at 6 months in pIpC-treated mice

nervous system

meningitis ( J:202090 )

• lymphoid infiltration in the meninges surrounding the brain at 6 months in pIpC-treated mice

renal/urinary system

enlarged kidney ( J:202090 )

• in diseased pIpC-treated mice

kidney inflammation ( J:202090 )

• lymphoid infiltration in the interstitial and perivascular space of the kidney at 6 months in pIpC-treated mice

hematopoietic system

enlarged thymus ( J:202090 )

• in diseased pIpC-treated mice

abnormal thymus physiology ( J:202090 )

• lymphoid infiltration in the thymus at 6 months in pIpC-treated mice

enlarged spleen ( J:202090 )

• in diseased pIpC-treated mice

anemia ( J:202090 )

• slightly at 6 months in pIpC-treated mice

thrombocytopenia ( J:202090 )

• severely at 6 months in pIpC-treated mice

abnormal leukocyte morphology ( J:202090 )

• monomorphic, enlarged white blood cells with a high nuclear:chromatin ratio (consistent with leukemic blasts) at 6 months in pIpC-treated mice

decreased pro-B cell number ( J:202090 )

• in pIpC-treated mice

arrested B cell differentiation ( J:202090 )

• nearly all B cells are arrested in the early pro-B stage of pIpC-treated mice

decreased double-positive T cell number ( J:202090 )

• in the thymus of pIpC-treated mice

decreased B cell number ( J:202090 )

• in the spleen of pIpC-treated mice

decreased mature B cell number ( J:202090 )

• in pIpC-treated mice

decreased pre-B cell number ( J:202090 )

• in pIpC-treated mice

increased leukocyte cell number ( J:202090 )

• at 6 months in pIpC-treated mice

increased CD8-positive, alpha-beta T cell number ( J:202090 )

• in the thymus of pIpC-treated mice

increased single-positive T cell number ( J:202090 )

• immature single positive cells in the thymus of pIpC-treated mice

increased large unstained cell number ( J:202090 )

• large, unstained cells (abnormal blasts) in the peripheral blood at 6 months in pIpC-treated mice

intermingled spleen red and white pulp ( J:202090 )

• disrupted separation between white and red pulp by infiltrating lymphoblasts at 6 months in pIpC-treated mice

endocrine/exocrine glands

enlarged thymus ( J:202090 )

• in diseased pIpC-treated mice

abnormal thymus physiology ( J:202090 )

• lymphoid infiltration in the thymus at 6 months in pIpC-treated mice